CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-11 | DUGAN RICHARD W Director | Grant or award | +5,000 | 45,641 | ||
| 2020-06-11 | DUGAN RICHARD W Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-06-11 | Chrousos Phaedra Director | Grant or award | +5,000 | 10,000 | ||
| 2020-06-11 | Chrousos Phaedra Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2020-05-29 | Watkins Thomas Director | Option exercise | +15,000 | $7.38 | $111K | 45,000 |
| 2020-05-29 | Watkins Thomas Director | Sale | −9,677 | $11.50 | $111K | 35,323 |
| 2020-05-29 | Watkins Thomas Director | Option exercise · Nonstatutory Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2020-05-28 | DUGAN RICHARD W Director | Option exercise | +15,000 | $7.38 | $111K | 50,770 |
| 2020-05-28 | DUGAN RICHARD W Director | Sale | −10,129 | $11.04 | $112K | 40,641 |
| 2020-05-28 | DUGAN RICHARD W Director | Option exercise · Nonstatutory Stock Option (Right to Buy) | −15,000 | 0 | ||
| 2020-03-03 | Williams Timothy SVP & General Counsel | Sale | −1,237 | $10.51 | $13K | 83,040 |
| 2020-03-03 | Polymeropoulos Mihael Hristos President and CEO | Sale | −5,152 | $10.98 | $57K | 1,278,999 |
| 2020-03-03 | Kelly James Patrick EVP & Chief Financial Officer | Sale | −5,889 | $10.76 | $63K | 186,869 |
| 2020-03-03 | Birznieks Gunther SVP, Business Development | Sale | −5,535 | $10.66 | $59K | 159,473 |
| 2020-03-02 | Williams Timothy SVP & General Counsel | Sale | −3,148 | $10.30 | $32K | 84,277 |
| 2020-03-02 | Reverberi Gian Piero SVP & Chief Commercial Officer | Sale | −1,450 | $10.18 | $15K | 165,384 |
| 2020-03-02 | Polymeropoulos Mihael Hristos President and CEO | Sale | −10,428 | $10.57 | $110K | 1,284,151 |
| 2020-03-02 | Kelly James Patrick EVP & Chief Financial Officer | Sale | −12,968 | $10.19 | $132K | 192,758 |
| 2020-03-02 | Birznieks Gunther SVP, Business Development | Sale | −12,223 | $10.04 | $123K | 165,008 |
| 2020-02-26 | Williams Timothy SVP & General Counsel | Grant or award | +30,000 | 87,425 |
Page 14 of 20 · 387 trades